Introduction
============

According to treatment guidelines^\[^[@B1]^\]^, higher-stage rectal cancer (T ≥3) is treated neoadjuvantly before surgical resection to reduce tumor size. This allows for less aggressive surgical procedures such as a total mesorectal excision (TME). Because preoperative chemoradiotherapy (CRT) shows a significant individual variation in treatment response^\[^[@B2; @B3; @B4]^\]^, early detection and assessment of response is the object of many studies^\[^[@B5; @B6; @B7; @B8; @B9]^\]^.

To assess therapy response early, functional magnetic resonance (MR) imaging studies are increasingly applied to add information on changes in tumor pathophysiology, e.g., tumor cellularity or changes in microcirculation during CRT, and thus may be sensitive to early CRT-induced changes. On the other hand, functional imaging such as diffusion-weighted (DW) imaging, because of its limited resolution, is less suitable for the depiction of tumor decline beyond anatomic margins required to monitor T-downstaging in rectal carcinoma. The definition of T stage in rectal cancer refers not to the tumor volume but only to the anatomic wall layers of the rectum, e.g., a T3-stage rectal cancer corresponds to a transgression of the muscularis propria^\[^[@B10]^,^[@B11]^\]^. A decrease in tumor volume, therefore, does not necessarily result in T-downstaging. Furthermore, tumor involvement of the radial circumferential resection margins (so-called CRM) has been shown to be an important prognostic factor. The aim of chemoradiation treatment is to render tumor regression so as to achieve a tumor-free resection margin^\[^[@B1]^\]^. However, in recent studies the response to treatment was defined as a reduction of anatomic T stage^\[^[@B12]^,^[@B13]^\]^, and this downstaging correlated with the diffusion-derived parameters. In these studies, the application of DW imaging to evaluate the early response of the primary rectal carcinoma to CRT showed conflicting results on considering the correlation of the diffusion values and tumor response.

Because radiation leads to necrosis^\[^[@B14]^\]^ as well as higher vascular permeability, an increase in the apparent diffusion coefficient (ADC)^\[^[@B15]^\]^ may be expected within 1 week of the first fraction of radiation therapy. This effect has been shown in previous studies of rectal cancer^\[^[@B13]^,^[@B16]^\]^. Sun et al.^\[^[@B13]^\]^ showed a significant increase of the ADC under treatment in T-downstaged responders, with no significant ADC increase in the non-downstaged group. Furthermore, they postulate a lower initial ADC in rectal downstaged carcinomas. By contrast (different *b* values being used in these studies), Dzik-Jurasz et al.^\[^[@B17]^\]^ reported a decrease in ADC correlating with percentage decrease in size of tumors, and Hein et al.^\[^[@B6]^\]^ showed a significant decrease of ADC for downstaged and non-downstaged tumors after neoadjuvant CRT.

The reason for these opposing findings is currently unclear. One possible explanation may be that a stronger inflammatory reaction in tumors being T-downstaged leads to increased perfusion, which in turn may lead to an increase in ADC values, since in the presence of perfusion effects the ADC reflects a combination of perfusion and tissue microstructure. The intravoxel incoherent motion (IVIM) model derives from a combined measure of the molecular movement of water (diffusion) and circulation of blood in the capillaries (perfusion) on DW imaging^\[^[@B18]^\]^. Of the derived perfusion-related parameters *f* and *D*\*, *f* is the more stable parameter, as shown both in numerical simulations^\[^[@B19]^\]^ and clinical studies,^\[^[@B20]^\]^ and is used in this study. Here we apply this technique to obtain a better understanding of the behavior of diffusion-derived parameters in patients with rectal carcinoma under CRT. We compare these parameters with the commonly used morphologic measure of treatment response, the decrease in volume, and the T-downstaging.

Materials and methods
=====================

Patients
--------

This prospective study was approved by our institutional review board, and written informed consent was obtained from all patients. Patients with primary histologically proven T3 or T4 adenocarcinoma of the rectum, with any nodal stage without metastatic spread and who were scheduled to undergo preoperative CRT, were included in this study. The initial tumor spread (T stage) was assessed using pelvic MR imaging and/or intrarectal ultrasonography. Infiltration of the perirectal fat was present in all patients. The clinical and histopathologic classification and stage grouping were in accordance with TNM classification after surgery. Patients with previous chemotherapy, abdominal surgery, or irradiation were excluded.

A total of 38 consecutive patients were recruited between May 2009 and July 2011. Twenty patients were excluded because of discontinued imaging during therapy, discontinued preoperative CRT, or delayed or canceled surgery. Eighteen patients with at least one follow-up under therapy (mean age, 61.7 years; age range, 40--83 years; 12 men and 6 women) were included ([Table 1](#T1){ref-type="table"}) using DW MR imaging at 3 time points: before CRT (within a week), at the end of the second week of CRT, and 1--4 days before surgery. Diffusion data from 13 patients were obtained at all 3 time points: In 5 patients no complete data set was obtained, in 2 cases data points were excluded because of technical measurement errors, and in 3 cases imaging was discontinued during follow-up. Table 1Summary of clinical findingsPatient no./age (years)Pre-/post-CRT T stageCircumferential resection margin pre-CRT (mm)1/403/202/623/203/633/304/713/205/833/306/614/207/504/408/733/309/783/2010/533/2011/633/3012/704/3013/313/3514/493/2015/524/3316/723/3017/673/3018/533/20

Rectal MR imaging
-----------------

All patients were examined with a 3-T MR scanner (Siemens Medical Solutions, Erlangen, Germany) with a gradient strength of 45 mT/m and using a 6-channel phased-array body coil. Imaging protocols included morphologic images as well as DW imaging according to the following parameters: T~2~-weighted turbo spin-echo in the sagittal and transverse plane, perpendicular to the long axis of the rectum covering the whole tumor (repetition time/echo time (TR/TE) = 4290/108 ms, slice thickness 3 mm) as well as T~2~-weighted SPACE (Sampling Perfection with Application optimized contrast using different flip-angle Evolutions) imaging in the sagittal plane (enabling reconstruction in any plane) (TR/TE = 1500/118 ms, slice thickness 3 mm). Axial DW images were acquired using a single-shot echo-planar imaging pulse sequence with the following imaging parameters: TR = 4100 ms, TE = 50 ms, field of view read 280-mm phase 75%, slice thickness = 3 mm, 4 averages, bandwidth = 2170 Hz/pixel, base resolution 128, k-space based parallel imaging technique with 24 reference lines (GRAPPA) acceleration factor of 2, *b* values = 0, 50, 100, 150, 200, 500, and 800 s/mm^2^. Forty milligrams of butylscopolammonium bromide (Buscopan; Boehringer Ingelheim Vetmedica, Ingelheim, Germany) was injected intravenously to reduce intestinal motion artifacts when contraindications had been excluded.

MR imaging analysis
-------------------

Representative T~2~-weighted MR images and DW MR images during treatment are shown in [Figs. 1](#F1){ref-type="fig"}a--c and [2](#F2){ref-type="fig"}a--c. The image quality of DW MR imaging was sufficient to identify the tumor region in all patients. Figure 1Images of 59-year-old man with rectal cancer. Axial fast spin-echo T~2~-weighted magnetic resonance (MR) imaging (a) pretherapy, (b) at the end of the second week of chemoradiotherapy (CRT), and (c) after CRT and before surgery, showing a volume reduction of 45%. Arrowheads indicate the tumor outline. Figure 2Axial diffusion-weighted (DW) MR images with *b* = 800 s/mm^2^, *D* values showing a narrow range: (a) pretherapy (*D* = 0.92 × 10^−3^ mm^2^/s), (b) at the end of the second week of CRT (*D* = 1.21 × 10^−3^ mm^2^/s), and (c) after CRT and before surgery (*D* = 1.20 × 10^−3^ mm^2^/s). Arrowheads indicate the tumor outline.

MR images were analyzed by 2 radiologists in consensus who were blinded to the therapeutic response. DW imaging values were generated across the entire segmented tumor volume. Therefore, the complete tumor volume was manually segmented (macroscopic necrosis was excluded) on DW-derived *b* = 800 s/mm^2^ images and contoured along the edge of the tumor in axial, coronal, and sagittal reconstruction ([Fig. 3](#F3){ref-type="fig"}a--c), section by section using software developed in-house (MITK Diffusion, Version 2011; DKFZ, Heidelberg, Germany). Figure 3Depiction of the region of interest (ROI) outline. ROI were drawn on DW MR images with a *b* value of 800 s/mm^2^. We manually contoured along the edge of the tumor as an ROI, section by section, in thicknesses of 3 mm, in sagittal (a), coronal (b), and transversal (c) orientation.

The thus derived segmented volume of the tumor was compared and adapted with the morphologic T~2~ data (see rectal MR data) to avoid erroneous tumor segmentation, and the tumor volume was derived from this segmentation. Mean volume, *D* value, and *f* value derived across the volume of interest of each patient were used for comparison with the tumor volume and the T-downstaging.

DW imaging-derived parameters were evaluated separately based on the IVIM model,^\[^[@B21]^\]^ yielding the parameters perfusion fraction *f* and diffusion constant *D*, using open-source software developed in-house (MITK Diffusion, Version 2011)^\[^[@B22]^\]^. The parameter estimation was based on the assumption that the diffusion measurement is influenced mainly by 2 effects, a perfusion-related effect introduced by the molecules moving in the capillary network (pseudodiffusion coefficient, *D*\*) and extravascular effects of passive diffusion (*D*). Since a simultaneous nonlinear fit for all parameters *D*, *D*\*, and the weighting coefficient *f* can be instable, measurement at *b* values greater than 170 s/mm^2^ were used in a first step to estimate *f* and *D* as proposed previously^\[^[@B23]^\]^. *D*\* was then calculated in a second step by using an exhaustive search. The procedure was implemented on the average measurements inside the manually encompassed tumor volume.

Histopathologic evaluation
--------------------------

After surgery, the resected specimens were staged according to the International Union Against Cancer TNM staging system^\[^[@B24]^\]^.

Treatment technique
-------------------

All patients underwent preoperative CRT. Radiotherapy to the pelvis (rectal canal and pelvic lymph nodes) was given in daily doses of 1.8 Gy per fraction to 45 Gy followed by a boost to the tumor bed to a total dose of 50.4 Gy, also in 1.8 Gy per fraction. In addition, chemotherapy was administered as continuous infusion of 5-fluorouracil (300 mg/m^2^ body surface) over 5 days from Monday to Friday throughout radiation therapy^\[^[@B25]^\]^. Four weeks after completion of CRT, patients underwent restaging including local imaging and rectoscopy, followed by TME 2--4 weeks thereafter.

Statistical analysis
--------------------

To analyze the correlation between the morphologic parameters and the diffusion values, all patients were assigned to one of two groups, the tumor downstaged or the tumor non-downstaged group. Tumor downstaging was assessed by comparing the pre-CRT clinical stage (cT stage) with the postoperative histopathologic stage (ypT stage). T-downstaging was defined when ypT was lower than cT. Values are reported as mean ± standard deviation. Pre- and post-treatment *D* and *f* values, and volume, were compared between the downstaged and non-downstaged groups using a *t* test.

Correlation between volume change and pretherapy *D* and *f* values and their changes from pretherapy to the end of the second week were investigated. Temporal changes of volume, *D* value, and *f* value were analyzed by evaluating the log of the ratio of the 2 values and performing one-sample *t* test.

Correlation between volume change and pretherapy *D* and *f* values and their changes from pretherapy to the end of the second week were investigated. Correlations were assessed by calculating the Spearman rank coefficient with 95% confidence interval. All statistical analyses were performed using SAS (version 9.2; SAS Institute, Cary, NC, USA). Two-tailed *P* values were used, and *P* values less than 0.05 were considered statistically significant.

Results
=======

Mean initial diffusion-derived parameters were located in a narrow range (initial *D*~1~ = 0.94 ± 0.12 × 10^−3^ mm^2^/s). At follow-up, *D* rose significantly (*D*~2~ = 1.18 ±  0.13 × 10^−3^ mm^2^/s; *P* \< 0.0001), and continued to increase significantly after CRT (*D*~3~ = 1.24 ± 0.14 × 10^−3^ mm^2^/s; *P* \< 0.0001 compared with *D*~1~). Following surgery, the histopathologic tumor downstaging/non-downstaging ratio was 10:8 patients. There was no complete response among the downstaged tumors. During CRT, the difference in mean tumor *D* value ([Fig. 4](#F4){ref-type="fig"}) was not significant for all time points (downstaged vs. non-downstaged *D*~1~ = 0.93 × 10^−3^ mm^2^/s vs. 0.95 × 10^−3^ mm^2^/s, *P* = 0.705; *D*~2~ = 1.23 × 10^−3^ mm^2^/s vs. 1.11 × 10^−3^ mm^2^/s, *P* = 0.0484; *D*~3~ = 1.30 × 10^−3^ mm^2^/s vs. 1.18 × 10^−3^ mm^2^/s, *P* = 0.204). No significant different behavior was detected for downstaged versus non-downstaged in increase of *D* values (*P* = 0.133 for the increase from initial to under therapy, *P* = 0.913 for the increase from initial to post-CRT). *D* values increased early in all but one patient ([Fig. 5](#F5){ref-type="fig"}). This patient did not show other aberrant parameters (e.g., histology, volume response to therapy). Figure 4Time course of *D* under therapy. The graph shows 18 lines that correspond to the mean tumor *D* value for each patient's time course during CRT. All patients but one (dashed line) showed an initial increase in *D* value. Figure 5Time course of volume under therapy. The graph shows 18 lines that correspond to the tumor volume time course during CRT for each patient. All patients but one (dashed line) showed a decrease in tumor volume.

*f* Values did not show differences over the time course (*f*~1~ = 9.4 ± 2.0%, *f*~2~ = 9.4 ± 1.7%, *f*~3~ = 9.5 ± 2.7%) nor any differences between downstaged and non-downstaged tumors (downstaged vs. non-downstaged *f*~1~ = 9.2% vs. 9.4%, *P* = 0.872; *f*~2~ = 9.4% vs. 9.3%, *P* = 0.840; *f*~3~ = 8.8% vs. 10.1%, *P* = 0.461).

Morphologic imaging-based volumetry showed a decrease in tumor volume in all patients but one ([Fig. 6](#F6){ref-type="fig"}). Mean volume (*V*) decreased during therapy (*V*~1~ = 16,992 ± 13,083 mm^3^; *V*~2~ = 12,793 ± 8317 mm^3^; *V*~3~ = 9718 ± 6154 mm^3^). There was a significant volume reduction under treatment for downstaged (*P* = 0.007) and non-downstaged (*P* = 0.015) tumors. Volume reduction, however, was not significantly different for the 2 groups (*P* = 0.724). There was no significant difference between the mean tumor volume of the 2 groups before and under treatment (*P* values for comparison at each time point 0.977, 0.932, and 0.102, respectively). Mean pretreatment tumor volume in the T-downstaged (13,374 mm^3^) group was lower than that in the non-downstaged group (21,301 mm^3^), (*P* = 0.98). The evolution of tumor volume in the 2 groups was not significantly different. There was no correlation between the *D* and *f* values and changes in volume ([Table 2](#T2){ref-type="table"}). The confidence intervals were large, covering relevant correlation values. Hence, it is possible that a larger study would show significant and relevant correlation. Figure 6Mean tumor *D* value for T-downstaged (gray line) and non-downstaged (dashed black line) during CRT. There was no statistical difference between the 2 groups. Table 2Volume changes correlated with the pretherapy *D*/*f* value, and with the early *D*/*f* value change at the end of the second weekVolume correlation parameter*r*95% CI*P* valuePretherapy *D* value−0.38−0.81--0.350.292Pretherapy *f* value0.02−0.62--0.640.96Early *D* value change end of 2nd week−0.25−0.78--0.510.53Early *f* value change end of 2nd week−0.23−0.77--0.520.56[^1]

Discussion
==========

DW MR imaging is a promising tool for the early detection of changes in tumors induced by CRT. However, the current literature shows conflicting results in changes of ADC values under CRT (decreasing vs. increasing values). We applied the IVIM model to further elucidate whether the underlying reason for these divergent reports can be attributed to microcirculation effects, e.g., increased perfusion caused by more pronounced inflammatory reactions. Decreases in diffusion-derived parameters were not observed, and the influence of microperfusion on diffusion values is negligible, since *f* did not change under therapy. Our data support the view that under effective therapy an increase in ADC is observed, potentially reflecting the loss of cell density resulting from CRT^\[^[@B26]^\]^ and micronecrosis (as macroscopic necrosis was largely excluded).

In our study we found significantly increasing *D* values in rectal carcinoma under chemotherapy and, simultaneously, a significant decrease in tumor volume. The evolution of diffusion values under CRT are in line with the results published by Sun et al.^\[^[@B13]^\]^. The conflicting reports of decreasing diffusion values as published by de Vries et al.^\[^[@B5]^\]^ and Dzik-Jurasz et al.^\[^[@B17]^\]^ could not be confirmed by the present study. DW imaging is sensitive to microscopic translational motion of water molecules that occur in each voxel whereby signal attenuation is influenced not only by diffusion processes but also by perfusion and other kinds of motion, summarized as IVIM. Therefore, when only one *b* value is used and the ADC is calculated, high ADCs under therapy may reflect a combination of increased perfusion and reduction of microstructure^\[^[@B27]^,^[@B28]^\]^. Thus, we investigated whether the contradictory results in ADC values could be due to strong radiation-induced inflammatory reactions and a resulting increase in *f*. We generally found a low perfusion fraction and, furthermore, *f* did not change significantly during therapy. Therefore the decrease in ADC values published by the groups of Hein, de Vries, and Dzik-Jurasz are unlikely to be related to microperfusion changes in the tumors, but it remains unclear as to why these early reports published results different from those in both our present study and another^\[^[@B13]^\]^. We found a relatively low perfusion fraction at baseline and no changes during follow-up examinations. In a previous report using dynamic T~1~-weighted contrast-enhanced maps of rectal carcinoma under CRT^\[^[@B29]^\]^, the perfusion also remained constant at 2 and 3 weeks after therapy. However, in this study a slight but significant increase in perfusion was found after 1 week. We did not acquire such an early time point, but our current data indicate that a similar change in *f* at such a time point is unlikely. Nonetheless, perfusion data derived from DW imaging has to be addressed with a certain care. A recent report shows that the perfusion-related parameters especially suffer from poor reproducibility^\[^[@B30]^\]^. In contrast to this study that performed a voxel-based fit of the data, we performed a fit based on the total volume of interest (VOI), thus increasing the fit stability.

A significant increase of *D* values for T-downstaged as well as non-downstaged tumors was found. As shown in animal studies and in human tumors^\[^[@B26]^,^[@B31]^,^[@B32]^\]^, this response occurs within days of initiating therapy and appears to be a relatively common response to therapy, regardless of pathologic categorization of the tumor.

Tumor downstaging in rectal carcinoma is not defined by volume decrease but by transgression of the tumor beyond an anatomic margin. Therefore, tumors that do show a volume reduction under CRT may not be T-downstaged. The T stage thus may be influenced predominantly by larger initial size rather than a different biological behavior; therefore, differences in changes in diffusion values under therapy between downstaged and non-downstaged tumors may not be expected. Contrary to our results, in the study by Sun et al.^\[^[@B13]^\]^ a significant increase in ADC was found only for the T-downstaged group, although similar volume reduction rates were reported for both groups. They postulated that sensitivity to chemoradiotherapy was higher in the downstaged group; however, we feel that their volumetric data seem to be discordant with the diffusion-derived response rate, since the volume reduction seems to be constant and similar for both groups after the first follow-up.

Comparable with the results of Sun et al.^\[^[@B13]^\]^, a significant volume reduction rate for T-downstaged and non-downstaged patients was shown in our study. A difference in initial ADC as found by Sun et al. could not be reproduced. Their findings are interpreted as resulting from stronger inflammatory reactions in the T-downstaged group, but again we feel that if there would have been a different biological reaction to therapy, the expected reduction rates of tumor volume should also have been different. Furthermore, in the study by Sun et al., non-downstaged patients presented with a higher initial volume than the downstaged group, what could have led to a bias in data analysis.

Hence, our results indicate that quantitative diffusion imaging may not be useful to differentiate between responders and nonresponders with rectal carcinoma after neoadjuvant CRT when response is defined as T-downstaging. When response is defined as volume reduction, DW imaging-derived measures are concordant with volumetric measurements.

Tumor volume measurement is widely used for antitumor therapy response, including rectal carcinoma^\[^[@B33]^\]^. However, its applicability in clinical routine is limited, as the rectum is a hollow organ with irregular morphology. The correlation between rectal tumor histopathologic downstaging after CRT and tumor volume reduction remains controversial^\[^[@B12]^,^[@B34]^,^[@B35]^\]^. The influence of T-downstaging on surgical treatment techniques is important, but the validation of T-downstaging as surrogate end point for long-term clinical outcome (overall survival and local control) in preoperative T3/T4 rectal cancer trials did not show any correlation^\[^[@B36]^\]^. Therefore, the T-downstaging may not have a strong relationship with the success of surgery or patient outcome. Curvo-Semedo et al.^\[^[@B4]^\]^ analyzed the relationship between tumoral ADC and histologic prognostic parameters, and found an aggressive histologic tumor profile to correlate with lower initial ADC values. Using the ADC, several groups showed promising results for better differentiation between post-therapeutic scar tissue (representing complete remission) and residual tumor in patients 1 month or more after completion of neoadjuvant CRT^\[^[@B9]^,^[@B37]^\]^.

This study has several limitations. First, the small sample size could have influenced the statistical results. However, if significant differences in diffusion values are not reproducible in smaller collectives, the additional value of diffusion data in clinical routine is limited. Although our VOI-based approach reduces the instability and, thus, the variance of parameter estimation, there is still a possibility that results may have been affected by the fact that MR images were analyzed by 2 radiologists in consensus without statistical tests of reproducibility. The aim of CRT is to render tumor regression so as to achieve a tumor-free resection margin^\[^[@B1]^\]^. Patients included in our study showed mostly advanced-stage disease with tumor involvement of the radial circumferential resection margins, and often not showing tumor regression after CRT from the mesorectal fascia, which could also proffer some bias. We tried to avoid slice-selection bias by segmenting the complete tumor volume, including only viable tumor, and excluding macroscopic necrosis. The identification of tumor downstaging in this study was based on a comparison between initial clinical T-staging and postoperative pathohistologic T-staging. This could have induced an inadvertent bias, because the clinical tumor stage pre-CRT would have been underestimated or overestimated in view of the inherent limitations of MR imaging and ultrasonography^\[^[@B38]^,^[@B39]^\]^.

Conclusion
==========

Applying the IVIM model, we were able to show that divergent results in the literature considering ADC changes in rectal carcinoma under CRT for patients showing T-downstaging are unlikely to be attributed to microperfusion effects. The microperfusion fraction *f* in rectal carcinoma under CRT is rather low and remains constant over time. Our data support the view that under effective therapy, an increase in *D* is observed.
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